CervoMed Unveils Findings at International Lewy Body Dementia Event
CervoMed to Present at the International Lewy Body Dementia Conference
BOSTON, Jan. 29, 2025 — CervoMed Inc. (NASDAQ: CRVO) is gearing up to present pivotal findings from its Phase 2b RewinD-LB study. This noteworthy presentation will take place at the prestigious International Lewy Body Dementia Conference (ILBDC), scheduled for January 31, 2025, in Amsterdam. CervoMed's research focuses on innovative solutions for age-related neurologic disorders, and this forthcoming presentation symbolizes a significant stride forward.
Highlights of the Presentation
The Phase 2b study concentrates on the efficacy and safety of neflamapimod in treating dementia with Lewy bodies (DLB). The primary topline findings for the study were previously revealed on December 10, 2024, and have generated considerable interest within the medical community.
Presentation Details
Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)
Format: Oral Presentation
Presenter: John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the study
Session Name: Symposium VIII-Therapy
Session Date and Time: January 31, 2025, 13:30 CET / 7:30 ET
Following the Conference
Once the conference concludes, detailed insights and data from the presentation will be made available through the Investor section of the CervoMed website. This initiative will provide stakeholders and interested parties access to further content regarding the findings of the research.
About CervoMed and Its Innovations
CervoMed Inc. remains dedicated to pioneering therapies for age-related neurologic disorders. At the heart of their research is neflamapimod, an investigational small molecule that can easily penetrate the brain. Designed to inhibit p38 mitogen-activated protein kinase alpha, neflamapimod aims to address synaptic dysfunction—a reversible element implicated in various neurodegenerative conditions.
Future Directions
There is a growing need for effective treatments within the domain of age-related neurologic disorders. With research like that of CervoMed, there is hope for patients suffering from DLB and related conditions. The company’s commitment to innovation and thorough clinical evaluation reinforces its position as a key player in the neurological field.
Contact Information for Investors
For investors seeking more information, CervoMed has provided contact details for further inquiries.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
Phone: 617-430-7579
Frequently Asked Questions
What will CervoMed present at the ILBDC?
CervoMed will present topline results from the Phase 2b RewinD-LB study on neflamapimod in dementia with Lewy bodies.
Who is presenting at the conference?
John Alam, MD, the CEO of CervoMed and Co-Principal Investigator of the study, will deliver the presentation.
When is the presentation taking place?
The presentation is scheduled for January 31, 2025, at 13:30 CET / 7:30 ET.
Where can I find more details after the presentation?
Details from the presentation will be available in the Investor section of CervoMed's website following the event.
What is neflamapimod?
Neflamapimod is an investigational drug designed to inhibit p38 mitogen-activated protein kinase alpha and aims to address synaptic dysfunction in age-related neurologic disorders.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
